IP Library › Granted Patent US 12,415,850
Granted Patent B2
US 12,415,850 · App. 18/432,991 · Granted Sep 16, 2025

Compositions and methods for regulating production of an antibody like protein and ribonucleic acid

Inventor: Bradley G. Thompson (Calgary, CA)
Assignee: Wyvern Pharmaceuticals Inc.
C07K16/1018A61P31/16C12N15/113C12N15/86C12N2310/141C12N2750/00043
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,415,850
App. No.
18/432,991
Granted
Sep 16, 2025
Kind
B2
Abstract

The present disclosure relates to one or more agents, therapies, treatments, and methods of use of the agents and/or therapies and/or treatments for producing an antibody like protein (ALP) and one or more sequences of miRNA that are complementary to the mRNA of a target, viral-specific protein or proteins. Embodiments of the present disclosure can be used as a therapy or a treatment for a subject that has a condition whereby the production of the APL and decreased production of a target, viral-specific protein or proteins may be of therapeutic benefit.

Claims (5)

1. A method of treating a subject with a condition, the method comprising a step of administering to the subject a therapeutic dose of a composition that comprises a recombinant plasmid (RP) with a sequence of nucleotides that comprise a start region, an end region and an insert positioned between the start region and the end region, wherein the insert encodes for production of an antibody-like protein (ALP) that is bindable with a surface protein of an influenza virus and a further sequence of micro-interfering ribonucleic acid (miRNA) that binds to and causes degradation of messenger ribonucleic acid (mRNA) that encodes for a target, viral protein of the influenza virus,

wherein the sequence of nucleotides of the insert comprises:

i) a sequence that comprises SEQ ID No: 1, and

ii) the further sequence that comprises SEQ ID No: 2.

2. The method of claim 1 , wherein the condition is an infection of the influenza virus.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 19, 2025
From: THOMPSON, BRADLEY G.
To: WYVERN PHARMACEUTICALS INC.
Reel/Frame 072057/0573 →
Continuity (2)
Continuation 18446965 · Aug 9, 2023
Related Publication 20250051424A1 · Feb 13, 2025
References Cited (35)
US 11085055B2 · Mallol et al. · 2021 [cited by applicant]
US 11162102B2 · Minshull et al. · 2021 [cited by applicant]
US 11530423B1 · Thompson · 2022 [cited by applicant]
US 11873505B2 · Thompson · 2024 [cited by applicant]
US 12018274B2 · Thompson · 2024 [cited by applicant]
US 12134770B1 · Thompson · 2024 [cited by applicant]
US 20200188456A1 · Weinstein · 2020 [cited by examiner]
US 20240026377A1 · Thompson · 2024 [cited by applicant]
CA 2721333A1 · 2009 [cited by applicant]
Del Rosario, et al. Front Immunol. May 29, 2020;11:627. doi: 10.3389/fimmu.2020.00627. PMID: 32547534. (Year: 2020). [cited by examiner]
Tang, et al. Mol Ther Nucleic Acids. Apr. 19, 2016;5(4):e311. doi: 10.1038/mtna.2016.25. PMID: 27093169. (Year: 2016). [cited by examiner]
O'Brien et al. “Overview of microRNA biogenesis, mechanisms of actions, and circulation.” Frontiers in endocrinology 9 (2018): 402. [cited by applicant]
Gorski et al. “RNA-based recognition and targeting: sowing the seeds of specificity.” Nature Reviews Molecular Cell Biology 18.4 (2017): 215-228. [cited by applicant]
Bottoni et al. “Targeting BTK through microRNA in chronic lymphocytic leukemia.” Blood, The Journal of the American Society of Hematology 128.26 (2016): 3101-3112. [cited by applicant]
Christensen et al. “Recombinant adeno-associated virus-mediated microRNA delivery into the postnatal mouse brain reveals a role for miR-134 in dendritogenesis in vivo.” Frontiers in neural circuits 3 (2010): 848. [cited by applicant]
Bofill-De Ros et al. “Guidelines for the optimal design of miRNA-based shRNAs.” Methods 103 (2016): 157-166. [cited by applicant]
Denzler et al. “Impact of microRNA levels, target-site complementarity, and cooperativity on competing endogenous RNA-regulated gene expression.” Molecular cell 64.3 (2016): 565-579. [cited by applicant]
Van Den Berg et al. “Design of effective primary microRNA mimics with different basal stem conformations.” Molecular Therapy Nucleic Acids 5 (2016). [cited by applicant]
Tritschler et al. “Concepts and limitations for learning developmental trajectories from single cell genomics.” Development 146.12 (2019): dev170506. [cited by applicant]
Ahmadzadeh et al. “BRAF mutation in hairy cell leukemia.” Oncology reviews 8.2 (2014): 253. [cited by applicant]
Patton et al. “Biogenesis, delivery, and function of extracellular RNA.” Journal of extracellular vesicles 4.1 (2015): 27494. [cited by applicant]
Clark et al. “Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies.” Oncotarget 11.44 (2020): 4016. [cited by applicant]
Wang et al. “Adeno-associated virus vector as a platform for gene therapy delivery.” Nature reviews Drug discovery 18.5 (2019): 358-378. [cited by applicant]
Kondratov et al. “Direct head-to-head evaluation of recombinant adeno-associated viral vectors manufactured in human versus insect cells.” Molecular Therapy 25.12 (2017): 2661-2675. [cited by applicant]
Nature (2010. Gene Expression. Scitable. Available online at Nature.com) <https://www.nature.com/scitable/topicpage/gene-expression-14121669> (2010). [cited by applicant]
Brutons Tyrosine Kinase Genbank Sequence (2023). [cited by applicant]
GenBank EGFR Sequence (2023). [cited by applicant]
GenBank EGF Sequence (2023). [cited by applicant]
NCBI search results for SEQ ID No. 5 (2024). [cited by applicant]
NCBI Nucleotide Sequence ALK Lingand, search performed Dec. 26, 2024 (2023). [cited by applicant]
NCBI Nucleotide Sequence ALK Receptor, search performed Dec. 26, 2024 (2023). [cited by applicant]
NCBI Nucleotide Sequence for PARP, search performed Dec. 26, 2024 (2024). [cited by applicant]
GenBank FLT3 Sequence (2024). [cited by applicant]
Martinez-Navio, et al. Immunity. Mar. 19, 2019; 50(3):567-575.e5. doi 10.1016/j.immuni.2019.02.005. epub Mar. 5, 2019. PMID: 30850342. (Year: 2019). [cited by applicant]
Ahluwalia, et al. Retrovirology. Dec. 23, 2008; 5:117. doi: 10118617424690-5-117. PMID: 19102781 (Year: 2008). [cited by applicant]